Main drivers were Beyfortus royalties ... as well as accelerated out-of-the-box Phase 6 studies, and in SG&A launch and pre-launch costs for Vonjo, out-of-the-box, and SEL-212.

TORONTO, Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

In the meantime, Sanofi remains “very confident” in the Beyfortus readouts it’s published thus far, he said. Speaking to the data on protection afforded by Beyfortus through six months ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of this immunization to ...

The beat was driven by a 19% surge in vaccine sales, attributed to the success of Beyfortus and the earlier-than-expected shipment of flu vaccines. Beyfortus, launched in partnership with Sobi ...

Wide-moat Sanofi reported better-than-expected third-quarter earnings driven by strong performance of the RSV prophylaxis drug Beyfortus and influenza vaccines. We've increased our fair value ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of ...